Manuel Litchman | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Manuel Litchman is active.

Explore More

Publication

Featured researches published by Manuel Litchman.

Blood | 1999

Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)

Ranjana H. Advani; Hussain I. Saba; Martin S. Tallman; Jacob M. Rowe; Peter H. Wiernik; Joseph Ramek; Kathleen Dugan; Bert L. Lum; Jenny Villena; Eric Davis; Elisabeth Paietta; Manuel Litchman; Branimir I. Sikic; Peter L. Greenberg

Archive | 1999

Use of epothilones for the treatment of cancer

Terence O'reilly; Markus Wartmann; Manuel Litchman; Pamela Cohen

Archive | 2006

Cancer treatment with epothilones

Terence O'Reilly; Markus Wartmann; Manuel Litchman; Pamela Cohen

Blood | 2013

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

Michael Kalos; Noelle V. Frey; Stephan A. Grupp; Alison W. Loren; Christina Jemision; Joan Gilmore; Holly McConville; James Capobianchi; Lester Lledo; Anne Chew; Angela Shen; Patricia A. Wood; Manuel Litchman; Zhaohui Zheng; Bruce L. Levine; Carl H. June

Blood | 2013

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Noelle V. Frey; Richard Aplenc; David M. Barrett; Anne Chew; Michael Kalos; Bruce L. Levine; Manuel Litchman; Shannon L. Maude; Susan R. Rheingold; Angela Shen; Christine Strait; David T. Teachey; Patricia A. Wood; David L. Porter; Carl H. June

Blood | 2014

Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas

Stephen J. Schuster; Jakub Svoboda; Sunita D. Nasta; David L. Porter; Elise A. Chong; Yolanda D. Mahnke; Simon F. Lacey; J. Joseph Melenhorst; Anne Chew; Gaurav D. Shah; Jens Hasskarl; Manuel Litchman; Mariusz A. Wasik; Daniel J. Landsburg; Anthony R. Mato; Alfred L. Garfall; Noelle V. Frey; Katherine T. Marcucci; Joanne Shea; Holly McConville; Zhaohui Zheng; Bruce L. Levine; Carl H. June

Blood | 2014

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

David L. Porter; Simon F. Lacey; Wei-Ting Hwang; Pamela A. Shaw; Noelle V. Frey; Anne Chew; Fang Chen; Michael Kalos; Vanessa Gonzalez; Katherine T. Marcucci; Shannon L. Maude; J. Joseph Melenhorst; Manuel Litchman; David T. Teachey; Angela Shen; Alfonso Quintas-Cardamas; Patricia A. Wood; Bruce L. Levine; Carl H. June; Stephan A. Grupp

Archive | 1999

Treatment of proliferative diseases, especially drug-resistant cancers - with epothilone B

Terence O'reilly; Markus Wartmann; Manuel Litchman; Pamela Cohen

Archive | 2013

meeting held in San Diego, CA, December 1997. 833 (Valspodar) : Presented in part at the American Society of Hematology Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With

Peter L. Greenberg; Kathleen Dugan; Bert L. Lum; Jenny Villena; Eric Davis; Elisabeth Paietta; Manuel Litchman; Hussain I. Saba; Martin S. Tallman; Jacob M. Rowe; Peter H. Wiernik; Joseph Ramek

Archive | 1999